ArticleScientific reports2026
Effect of Sun's Bushen Huayu formula on M1/M2-associated markers and endometrial repair in a thin endometrium model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The presence of thin endometrium (TE) and defective embryo implantation, indicative of endometrial disorders, majorly contributes to sterility. The Sun's Bushen Huayu formula (BHD), a multi-herbal decoction prepared under standardized conditions, has shown potential in modulating M1/M2-associated inflammatory markers, but its efficacy in endometrial repair remains unclear. Female Sprague-Dawley rats with confirmed regular estrous cycles were first subjected to a thin endometrium (TE) model induced by hydroxyurea, high-molecular dextran, and intrauterine ethanol injury. After model establishment, rats received oral BHD or vehicle for 20 days, then were mated. On gestational day 8, uterine tissues were collected for analysis. Estrous cycle synchronization, body weight dynamics, embryo count, and histopathological evaluation were performed. Immunohistochemistry for M1/M2 macrophage markers, cytokine profiling by ELISA, and molecular analyses (qRT-PCR, flow cytometry) of M1/M2-associated markers and endometrial repair markers were conducted. In addition, western blotting was performed to examine STAT3 activation, apoptosis-related proteins, and nuclear/cytoplasmic NF-κB signaling. The administration of BHD notably lessened body weight loss and improved reproductive outcomes, as indicated by increased embryo implantation compared with the Model group, although implantation was not fully restored to Control levels. Representative histological analysis showed that BHD improved endometrial morphology. Treatment with BHD altered the expression of M1- and M2-associated markers, as evidenced by elevation of Arg-1 (an M2-related marker) and reduction of iNOS (an M1-related marker) in uterine tissue. Mechanistically, BHD was associated with a reduced p-STAT3/STAT3 ratio, decreased Cleaved-Caspase-3 and Bax expression, restored Bcl-2 levels, lower nuclear p-NF-κB/NF-κB, and higher cytoplasmic p-NF-κB/NF-κB, suggesting attenuation of inflammatory-apoptotic signaling and a shift in NF-κB subcellular distribution. Molecular analyses confirmed BHD's role in shifting the balance of M1/M2-associated markers, increasing CD206
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.